Nijmegen, The Netherlands – April 7, 2011 – Syntarga B.V., the emerging Antibody- Drug Conjugate (ADC) company, announces today that it entered into a number of new research collaboration agreements since its May 2010 press release. During this period, collaboration agreements have been executed with multiple top-20 biopharmaceutical companies, as well as with multiple biotech companies.
ADCs are being evaluated by the Company’s collaborators in which the newest Syntarga Linker-Drug chemistries are linked to collaborator antibodies. The Company has recently presented biological data for its current ADC chemistries at international conferences. “The exciting data generated for ADCs based on our optimized Linker-Drugs vis-à-vis multiple established technologies, with regards to both efficacy and safety, have triggered significant interest from top-tier (bio)pharma players. The growing package of biological data for ADCs based on Syntarga technology against a variety of antigen targets underscores the broad potential of the Company’s unique, proprietary technologies.” said Dr. Vincent de Groot, Chief Executive Officer of Syntarga.
About Syntarga BV
Syntarga is a privately held biopharmaceutical company engaged in the discovery and development of proprietary Antibody-Drug Conjugate technology and products for the treatment of cancer. The Company’s cutting-edge chemistry capabilities and unique know-how have led to the creation of its antibody empowering Potent Payload Technology. Syntarga is leveraging its proprietary technologies and expertise to generate and commercialize, alone and with partners, a portfolio of next generation Antibody-Drug Conjugate products. For more information about Syntarga, visit its website at www.syntarga.com.
Contact:
Vincent de Groot, Ph.D., CLP T
CEO, Syntarga B.V. E
T: +31 24 3652 878
E: fmhdegroot@syntarga.com
Source: Syntarga B.V.
